Triterpenoid saponin compound with activity of inhibiting liver fat accumulation as well as extraction method and application of triterpenoid saponin compound
Patent Information
- Application Number
- CN202410967908.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-22
AI Technical Summary
但目前对其化学成分及药理活性研究极少,更没有对其进行提取而得到抑制肝脂肪堆积作用的活性化合物
[0028] The chemical names of the triterpene saponins provided by the invention are triterpene saponin-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside and triterpene saponin. -3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside. The extraction method of triterpene saponins provided by the invention is obtained by sequentially extracting by dipping, extracting with solvents of different polarities, and separating by various column chromatography and semi-preparative high-performance liquid chromatography. The extraction method is simple in process, low in cost, non-toxic, No pollution, suitable for large-scale promotion and application; the triterpene saponins of the present invention have significant inhibitory effects The generation of triglycerides in the hepatic lipid accumulation cell model constructed with HepG2 human hepatoma cells or mouse primary hepatocytes (MPH) induced by oleic acid/palmitic acid (OA/PA) showed better inhibition of hepatic lipid accumulation. It can be used as health food, functional food or potential medicine to prevent or treat non-alcoholic fatty liver disease.
Smart Images

Figure CN118994292A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicine, and in particular relates to a triterpenoid saponin compound having the activity of inhibiting liver fat accumulation, and an extraction method and application thereof. Background Art
[0002] Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease characterized by excessive lipid accumulation in the liver. It has a high incidence rate and currently has no definite clinical treatment. Therefore, there is an urgent need to find and develop drugs with efficient prevention or treatment effects.
[0003] Extensive phytochemical studies have shown that plants of the genus Rubus L in the family Rosaceae are rich in triterpenes, diterpenes, flavonoids and other chemical components, which have significant biological activities, such as antioxidant, anti-inflammatory and antibacterial, anti-hyperglycemic, anti-hyperlipidemia and liver protection effects.
[0004] Rubus setchuenensis is a plant of the genus Rubus (Rubus L), endemic to China, mainly distributed in Hubei, Hunan and southwest my country. Both its roots and leaves can be used as medicine, and have important medicinal development value. However, there are very few studies on its chemical composition and pharmacological activity, and there is no active compound extracted from it to inhibit liver fat accumulation. Summary of the invention
[0005] In view of this, the present invention proposes a triterpenoid saponin compound having the activity of inhibiting liver fat accumulation and an extraction method and application thereof, so as to solve the technical problems existing in the prior art.
[0006] The present invention separates two new triterpenoid saponin compounds from the root of Raspberry, which have a significant effect of inhibiting liver fat accumulation and can be used as potential drugs for preventing or treating non-alcoholic fatty liver disease. Specifically, the technical scheme of the present invention is as follows:
[0007] In a first aspect, the present invention provides a triterpenoid saponin compound, wherein the triterpenoid saponin compound comprises tribenzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside or tribenzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside;
[0008] The chemical structure of the tri-benzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside is as follows:
[0009]
[0010] The chemical structural formula of the tri-benzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside is as follows:
[0011]
[0012] In a second aspect, the present invention further provides a method for extracting the triterpenoid saponin compound, comprising the following steps:
[0013] The dried raspberry root is crushed and then soaked in ethanol at room temperature for multiple times, and the soaking liquid is filtered each time, and the soaking liquid is collected and combined, and concentrated under reduced pressure to obtain an extract;
[0014] The extract is suspended in water to form an aqueous suspension, and extracted with petroleum ether, dichloromethane, ethyl acetate, and n-butanol in sequence, and the extract is separated and concentrated under reduced pressure to obtain an extract of the petroleum ether extraction part, an extract of the dichloromethane extraction part, an extract of the ethyl acetate extraction part, and an extract of the n-butanol extraction part in sequence;
[0015] The extract of the ethyl acetate extraction part was separated by silica gel column chromatography, and a dichloromethane-methanol mixture was used as an eluent for gradient elution, and thin layer detection was performed, and fractions with similar components were combined to obtain 10 fractions H1 to H10;
[0016] Fraction H1 was separated by gel column chromatography and eluted with methanol to obtain five secondary fractions H1.1 to H1.5;
[0017] The triterpenoid saponin compound was prepared by semi-preparative high performance liquid chromatography on fraction H1.1.
[0018] Preferably, the dried raspberry root is crushed and then extracted by soaking in 92-98% ethanol by volume at room temperature for 2-4 times, and the soaking liquid is filtered each time, and the soaking liquid is collected and combined, and concentrated under reduced pressure to obtain an extract.
[0019] Preferably, the dried raspberry root is suspended in water to form an aqueous suspension, and then extracted with petroleum ether, dichloromethane, ethyl acetate and n-butanol in sequence. The extract is separated and separated each time to obtain an extract, which is concentrated under reduced pressure to obtain an extract of the petroleum ether extraction part, an extract of the dichloromethane extraction part, an extract of the ethyl acetate extraction part and an extract of the n-butanol extraction part in sequence; wherein each kg of the extract is suspended in 5-10 L of water to form an aqueous suspension, and the volume ratio of the petroleum ether, dichloromethane, ethyl acetate and n-butanol to water is (1-3):(1-3), respectively.
[0020] Preferably, in the step of separating the extract of the ethyl acetate extraction part by silica gel column chromatography and performing gradient elution with a dichloromethane-methanol mixture as the eluent, the mesh number of the silica gel column is 200-300 meshes, and the volume ratio of dichloromethane to methanol is 30:1-1:1.
[0021] Preferably, fraction H1 is separated by Sephadex LH-20 gel column chromatography and eluted with pure methanol to obtain five secondary fractions H1.1 to H1.5.
[0022] Preferably, fraction H1.1 is separated by semi-preparative high performance liquid chromatography, the chromatographic column used is a C18 chromatographic column, the chromatographic column length is 250 mm, the chromatographic column inner diameter is 10 mm, the chromatographic column filler particle diameter is 5 μm, and a mixed solution obtained by mixing pure methanol and a formic acid aqueous solution with a volume concentration of 0.01 to 0.05% is used as an eluent for isocratic elution to obtain a triterpenoid saponin compound;
[0023] Collect R The fraction from 31.0 to 33.0 min gave tris-benzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside;
[0024] Collect R The fraction from 39.0 to 41.0 min gave tri-benzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside.
[0025] Preferably, in the step of mixing pure methanol and a formic acid aqueous solution with a volume concentration of 0.01 to 0.05% to obtain a mixed solution, the volume fraction of methanol in the mixed solution is 68 to 72%.
[0026] In a third aspect, the present invention also provides a use of the triterpenoid saponin compound in the preparation of health food, functional food or medicine for preventing or treating non-alcoholic fatty liver disease.
[0027] The triterpenoid saponin compound having the activity of inhibiting liver fat accumulation and the extraction method and application thereof of the present invention have the following beneficial effects compared with the prior art:
[0028] The chemical names of the triterpenoid saponin compounds provided by the present invention are tribenzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-pyranoarabinoside and tribenzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-pyranoxyloside. The extraction method of the triterpenoid saponin compounds provided by the present invention is obtained by immersion extraction, extraction with solvents of different polarities, separation by multiple column chromatography and semi-preparative high performance liquid chromatography in sequence. The extraction method is simple in process, low in cost, non-toxic and pollution-free, and suitable for large-scale promotion and application; the triterpenoid saponin compounds of the present invention have the ability to significantly inhibit the production of triglycerides in a liver fat accumulation cell model constructed by HepG2 human liver cancer cells or mouse primary hepatocytes (MPH) induced by oleic acid / palmitic acid (OA / PA), showing a good effect of inhibiting liver fat accumulation, and can be used to prepare health food, functional food or potential medicine for preventing or treating non-alcoholic fatty liver. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0030] Figure 1 This is a high resolution mass spectrum (HR-ESI-MS) of compound 1 extracted and separated in Example 1;
[0031] Figure 2 This is the infrared spectrum of compound 1 extracted and separated in Example 1;
[0032] Figure 3 The compound 1 obtained by extraction and separation in Example 1 1 HNMR spectrum;
[0033] Figure 4 The compound 1 obtained by extraction and separation in Example 1 13 C NMR spectrum;
[0034] Figure 5 This is a high resolution mass spectrum (HR-ESI-MS) of compound 2 extracted and separated in Example 1;
[0035] Figure 6 This is the infrared spectrum of compound 2 extracted and separated in Example 1;
[0036] Figure 7 The compound 2 obtained by extraction and separation in Example 1 1 HNMR spectrum;
[0037] Figure 8 The compound 2 obtained by extraction and separation in Example 1 13 C NMR spectrum;
[0038] Fig. 9 This is a graph showing the effect of compounds 1-2 extracted and separated in Example 1 on inhibiting the accumulation of hepatic lipids in HepG2 cells treated with OA / PA;
[0039] Fig.10 This is a graph showing the effect of compounds 1-2 extracted and separated in Example 1 on inhibiting hepatic lipid accumulation in primary hepatocytes of mice treated with OA / PA. DETAILED DESCRIPTION
[0040] In order to make the purpose, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0041] In order to better understand the present invention but not to limit the scope of the present invention, all the numbers used in this application to express the amount, percentage, and other numerical values should be understood as modified by the word "about" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the appended claims are approximate values, which may be changed according to the different ideal properties attempted to be obtained. Each numerical parameter should at least be regarded as obtained based on the reported significant figures and by conventional rounding methods.
[0042] It should be noted that the order of description of the following embodiments is not intended to limit the preferred order of the embodiments. In addition, in the description of the present application, the term "including" means "including but not limited to". Various embodiments of the present invention may be in the form of a range; it should be understood that the description in the form of a range is only for convenience and brevity, and should not be understood as a rigid limitation on the scope of the present invention; therefore, it should be considered that the range description has specifically disclosed all possible sub-ranges and single numerical values within the range. For example, it should be considered that the range description from 1 to 6 has specifically disclosed sub-ranges, such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6, etc., as well as single numbers within the numbered range, such as 1, 2, 3, 4, 5 and 6, which applies regardless of the range. In addition, whenever a numerical range is indicated in this article, it is meant to include any cited numbers (fractions or integers) within the indicated range.
[0043] The present invention provides a triterpenoid saponin compound, the triterpenoid saponin compound comprising tribenzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside or tribenzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside;
[0044] Among them, tri-benzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside (molecular formula C 39 H 58 O 11 ) has the following chemical structure:
[0045]
[0046] Tribenzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside (molecular formula: C 39 H 58 O 11 ) has the following chemical structure:
[0047]
[0048] In the structural formula of the above triterpenoid saponin compound, AcO represents an acetoxy group.
[0049] Based on the same inventive concept, the present invention also provides a method for extracting the above-mentioned triterpenoid saponin compounds, comprising the following steps:
[0050] S1. Crush the dried raspberry roots, soak and extract them with ethanol at room temperature for multiple times, filter the soaking liquid each time, collect and combine the soaking liquids, and concentrate under reduced pressure to obtain an extract;
[0051] S2, suspending the extract in water to form an aqueous suspension, extracting with petroleum ether, dichloromethane, ethyl acetate, and n-butanol in sequence, separating and obtaining extracts each time, and concentrating under reduced pressure to obtain extracts of the petroleum ether extraction part, the dichloromethane extraction part, the ethyl acetate extraction part, and the n-butanol extraction part in sequence;
[0052] S3, taking the extract of the ethyl acetate extraction part, separating it by silica gel column chromatography, using a dichloromethane-methanol mixture as an eluent for gradient elution, thin layer detection, combining the fractions of similar components, and obtaining 10 fractions H1 to H10;
[0053] S4, separating fraction H1 by gel column chromatography, and eluting with methanol to obtain five secondary fractions H1.1 to H1.5;
[0054] S5. The fraction H1.1 is subjected to semi-preparative high performance liquid chromatography to obtain triterpenoid saponin compounds.
[0055] In some embodiments, the dried raspberry root is crushed and then extracted with 92-98% ethanol by volume at room temperature (25°C) for 2-4 times, and the extract is filtered each time, collected and combined, and concentrated under reduced pressure to obtain an extract.
[0056] In some embodiments, the extract is suspended in water to form an aqueous suspension, and extracted with petroleum ether, dichloromethane, ethyl acetate, and n-butanol in sequence. The extract is separated and separated each time to obtain an extract, which is concentrated under reduced pressure to obtain an extract of the petroleum ether extraction site, an extract of the dichloromethane extraction site, an extract of the ethyl acetate extraction site, and an extract of the n-butanol extraction site in sequence; wherein each kg of extract is suspended in 5-10 L of water to form an aqueous suspension, and the volume ratio of the petroleum ether, dichloromethane, ethyl acetate, and n-butanol to water is (1-3):(1-3), respectively.
[0057] In some embodiments, the extract of the ethyl acetate extraction part is separated by silica gel column chromatography, and in the step of gradient elution using a dichloromethane-methanol mixture as an eluent, the mesh size of the silica gel column is 200-300 meshes, and the volume ratio of dichloromethane to methanol is 30:1-1:1.
[0058] In some embodiments, fraction H1 is separated by Sephadex LH-20 gel column chromatography and eluted with pure methanol to obtain five sub-fractions H1.1 to H1.5.
[0059] In some embodiments, fraction H1.1 is separated by semi-preparative high performance liquid chromatography, the chromatographic column used is a C18 chromatographic column, the chromatographic column length is 250 mm, the chromatographic column inner diameter is 10 mm, the chromatographic column filler particle diameter is 5 μm, and a mixture obtained by mixing pure methanol and a formic acid aqueous solution with a volume concentration of 0.01 to 0.05% is used as an eluent for isocratic elution to obtain a triterpenoid saponin compound;
[0060] Collect R The fraction from 31.0 to 33.0 min gave tris-benzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside;
[0061] Collect R The fraction from 39.0 to 41.0 min gave tri-benzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside.
[0062] In some embodiments, in the step of mixing pure methanol and an aqueous formic acid solution with a volume concentration of 0.01 to 0.05%, the volume fraction of methanol in the mixed liquid is 68 to 72%. Preferably, the volume fraction of methanol in the mixed liquid is 70%, that is, pure methanol and an aqueous formic acid solution with a volume concentration of 0.01 to 0.05% are mixed in a volume ratio of 7:3 to obtain the mixed liquid.
[0063] In some embodiments, the dried berry roots are crushed and then extracted multiple times by soaking in ethanol at room temperature, wherein the mass volume ratio of the berry roots used to the ethanol used each time is (7-12) kg: (20-30) L.
[0064] Based on the same inventive concept, the present invention also provides an application of the above-mentioned triterpenoid saponin compound in the preparation of health food, functional food or medicine for preventing or treating non-alcoholic fatty liver disease.
[0065] The present invention provides two new triterpenoid saponin compounds with the activity of inhibiting liver fat accumulation and their extraction methods. The chemical names of the triterpenoid saponin compounds of the present invention are tribenzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-pyranoarabinoside and tribenzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-pyranoxyloside. The extraction methods of the two new triterpenoid saponin compounds provided by the present invention are sequentially obtained by immersion extraction, extraction with solvents of different polarities, separation with multiple column chromatography and semi-preparative high performance liquid chromatography. The extraction method is simple in process, low in cost, non-toxic, pollution-free, and suitable for large-scale promotion and application. The triterpenoid saponin compounds of the present invention have the ability to significantly inhibit the production of triglycerides in a liver fat accumulation cell model constructed by HepG2 human liver cancer cells or mouse primary hepatocytes (MPH) induced by oleic acid / palmitic acid (OA / PA), showing a good effect of inhibiting liver fat accumulation, and can be used to prepare health foods, functional foods or potential drugs for preventing or treating non-alcoholic fatty liver disease.
[0066] The triterpenoid saponin compounds and extraction methods and applications of the present application are further described below with specific examples. This section further illustrates the present invention in conjunction with specific examples, but should not be construed as limiting the present invention. If not specifically stated, the technical means adopted in the embodiments are conventional means well known to those skilled in the art. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.
[0067] Example 1
[0068] This embodiment provides a triterpenoid saponin compound, the triterpenoid saponin compound comprising tribenzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside or tribenzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside;
[0069] The method for extracting the triterpenoid saponin compound comprises the following steps:
[0070] S1. 9.36 kg of dried berry roots were crushed and then soaked and extracted three times with 25 L of 95% ethanol by volume at room temperature, and the soaking liquid was filtered each time. The soaking liquid was collected and combined, and concentrated under reduced pressure to obtain 610.21 g of extract;
[0071] S2, suspend the extract in S1 in 2.5L water to form an aqueous suspension, extract with petroleum ether, dichloromethane, ethyl acetate, and n-butanol for 3 times, separate the extracts each time, combine the extracts, and concentrate under reduced pressure to obtain 37.5321g of extract from the petroleum ether extraction part, 43.5g of extract from the dichloromethane extraction part, 74.9g of extract from the ethyl acetate extraction part, and 404.2g of extract from the n-butanol extraction part; wherein the volume ratio of petroleum ether, dichloromethane, ethyl acetate, and n-butanol to water is 1:1;
[0072] S3, taking the extract of the ethyl acetate extraction part, separating it by chromatography on a silica gel column (mesh number of 200-300 mesh), using a dichloromethane-methanol mixture as an eluent for gradient elution, thin layer detection, combining the fractions of similar components, and obtaining 10 fractions H1-H10; wherein, the volume ratios of dichloromethane and methanol during the gradient elution process are 30:1, 20:1, 10:1, 5:1, 2:1, and 1:1, respectively;
[0073] S4, fraction H1 was separated by Sephadex LH-20 gel column chromatography, and eluted with methanol to obtain five secondary fractions H1.1 to H1.5;
[0074] S5. Separating the fraction H1.1 by semi-preparative high performance liquid chromatography, using a C18 column (specifically, an Xbridge Prep C18 column (10 mm×250 mm, 5 μm)) as the chromatographic column, and performing isocratic elution using a mixed solution obtained by mixing pure methanol and a 0.05% by volume formic acid aqueous solution (the volume fraction of methanol in the mixed solution is 70%) as the eluent to obtain a triterpenoid saponin compound;
[0075] Collect R The fraction at 32.0 min gave 70.0 mg of compound 1 (ie, tribenzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside);
[0076] Collect R The fraction at 40.0 min gave 36.9 mg of compound 2 (ie, tribenzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside).
[0077] Characterization of triterpenoid saponin compounds
[0078] The compound 1 obtained in the above Example 1 is a white amorphous powder; the high resolution mass spectrum (HR-ESI-MS) of the compound 1 is as follows: Figure 1 As shown, m / z 701.4004[MH] - (Theoretical calculated value C 39 H 57 O 11 - , 701.3906); the infrared spectrum (KBr) of compound 1 is as follows Figure 2 As shown, v max =3460, 2943, 2875, 1734, 1465, 1377cm -1 ; Compound 1 1 H NMR (400 MHz, Pyr-d5) Figure 3 As shown, Figure 3 Medium δ5.84-5.77(1H,m,Ara-H-2'),5.57-5.51(1H,m,Ara-H-4'),5.54(1H,m,H-12),4.74(1H,d,J=7.8Hz,Ara-H-1'),4.33(1H,dd,J=9 .9,3.7Hz,Ara-H-3'),4.25(1H,dd,J=13.1,2.0Hz,Ara-H-5'),3.85(1H,d,J=12.3Hz,Ara-H-5'),3.45(1H,dd,J=13.8,3.9Hz,H-19 ),3.21(1H,dd,J=11.7,4.4Hz,H-3),2.61(1H,t,J=13.9Hz,H-19),2.12(3H,s,2'-COCH3),1.82(3H,s,4'-COCH3),1.60(3H,s,H-30),1.30(3H,s,H-27),1.10(3H,s,H-23),1.00(3H,s,H-26),0.91(3H,s,H-24),0.81(3H,s,H-25),0.77(1H,d,J=11.3Hz,H-5); 13 C NMR (100 MHz, Pyr-d5) Figure 4 As shown, Figure 4Medium δ181.49(C-29),180.35(C-28),171.07(2'-COCH3),170.43(4'-COCH3),144 .64(C-13),123.35(C-12),104.85(Ara-C-1'),89.34(C-3),74.40(C-2'),72 .80(C-4'),70.63(C-3'),64.87(C-5'),55.98(C-5),48.30(C-9),46.96(C-1 7),42.91(C-20),42.48(C-14),41.41(C-18;C-19),40.06(C-8),39.54(C-4) ,38.79(C-1),37.30(C-10),33.47(C-7),32.72(C-22),29.60(C-21),28.62(C-15),28.23(C-23),26.82(C-2),26.41(C-27),24.16(C-11;C-16),21.58(2'-COCH3),21.18(4'-COCH3),20.39(C-30),18.80(C-6),17.70(C-26),17.12(C-24),15.70(C-25); Compound 1 was identified as: tri-p-benzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside.
[0079] The compound 2 obtained in the above Example 1 is a white amorphous powder; the high resolution mass spectrum (HR-ESI-MS) of the compound 2 is as follows: Figure 5 As shown, m / z 701.3988[MH] - (Theoretical calculated value C 39 H 57 O 11 - , 701.3906); the infrared spectrum (KBr) of compound 2 is as follows Figure 6 As shown, v max =3412, 2943, 1718, 1380, 1274cm -1 ; Compound 2 1 H NMR (400 MHz, Pyr-d5) Figure 7 As shown, Figure 7Medium δ6.04-5.95(1H,m,Xyl-H-2'),5.54(1H,m,H-12),5.47-5.41(1H,m,Xyl-H-3'),4.81(1H,d,J=7.2Hz,Xyl-H-1'),4.55-4.48(1 H, m, 1H, dd, J = 11.6, 4.3 Hz, H-3), 2.61 (1H, t, J = 13.9 Hz, H-19), 2.16 (3H, s, 2'-COCH3), 1.96 (3H, s, 3'-COCH3), 1.60 (3H, s, H-30), 1.30 (3H, s, H-27), 1.07 (3H, s, H-23), 1.01 (3H, s, H-26), 0.88 (3H, s, H-24), 0.83 (3H, s, H-25), 0.77 (1H, d, J = 11.2 Hz, H-5); Compound 2 13 C NMR (100 MHz, Pyr-d5) Figure 8 As shown, Figure 8Medium δ181.64(C-29),180.46(C-28),170.92(2'-COCH3),170.11(3'-COCH3),144.72(C-13),123.35(C-12),104.27(Xyl-C-1'),89.28(C-3),74 .74(C-3'),71.16(C-2'),67.26(C-4'),67.11(C-5'),55.98(C-5),48 .33(C-9),47.01(C-17),42.96(C-20),42.52(C-14),41.46(C-18;C-19 ),40.09(C-8),39.54(C-4),38.84(C-1),37.35(C-10),33.50(C-7),3 2.78(C-22),29.67(C-21),28.65(C-15),28.28(C-23),26.72(C-2),2 6.44(C-27),24.19(C-11;C-16),21.33(2'-COCH3),21.14(3'-COCH3),20.44(C-30),18.83(C-6),17.74(C-26),17.12(C-24),15.74(C-25). Compound 2 was identified as tri-p-benzyloxyphenol-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside.
[0080] The scifinder database search showed that compounds 1 and 2 were new compounds.
[0081] Example 2
[0082] This example evaluates the lipid-lowering activity of the triterpenoid saponin compounds 1 to 2 isolated in Example 1. Specifically, the lipid-lowering activity evaluation method is as follows: HepG2 human liver cancer cells and freshly extracted mouse primary hepatocytes (MPH) were inoculated in 6-well plates and cultured until adherence. Except for the blank group, the culture medium of the model group and the drug-treated group was replaced with TG induction solution (complete culture medium containing 0.5 mM sodium oleate (OA) and 0.25 mM sodium palmitate (PA) and 10% BSA). After incubation for 24 hours, the culture medium of the blank group and the model group was replaced with complete culture medium, and the drug-treated group was replaced with complete culture medium containing compound 1 or 2 at a concentration of 40 μM. The positive control group was a complete culture medium containing 10 μM obeticholic acid (OCA). After 24 hours, the cells were washed three times with PBS, 150 μL of lysis solution was added to each well, and the lysis was carried out for 30 minutes. The supernatant was aspirated and placed in 1.5 mL EP tubes were placed in a 70°C water bath and a portion of the supernatant was diluted ten-fold to measure the protein concentration. The EP tubes were placed in a 70°C water bath for 10 minutes, centrifuged at 2000 rpm for 5 minutes at room temperature, and the supernatant was added with the working solution and reacted at 37°C for 20 minutes. The OD value was detected at a wavelength of 550nm and divided by the corresponding protein concentration to calculate the triglyceride (TG) level. The TG content of the model group was set to 100%, and the relative TG content of the other groups was calculated.
[0083] The results of lipid-lowering activity experiments are as follows Figures 9-10 As shown; among them, Figures 9-10 In the table, control means blank group, model means model group, compound1 means compound 1 (i.e., tri-paired benzylic acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside) administration group, compound2 means compound 2 (i.e., tri-paired benzylic acid-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside) administration group, and OCA means positive control group; Fig. 9 ####P<0.0001vs control; ****P<0.0001vs model; Fig.10 ####P<0.0001vs control; ***P<0.001vs model.
[0084] from Figures 9-10It can be seen that compared with the blank group, the TG content of the two liver lipid accumulation model groups induced by TG induction solution (OA / PA) was extremely significantly increased (P<0.0001), while compared with the HepG2 cell liver lipid accumulation model group treated with OA / PA, the TG content of the compound 1 and 2 administration groups was extremely significantly reduced (P<0.0001), significantly inhibiting liver fat accumulation, with inhibition rates of 53.26% and 51.65%, respectively; compared with the mouse primary hepatocyte (MPH) lipid accumulation model group treated with TG induction solution (OA / PA), the TG content of the compound 1 or 2 administration group was also significantly reduced (P<0.0001), with inhibition rates of 37.40% and 43.21%, respectively, which indicates that compounds 1 and 2 have good lipid-lowering potential in vitro at a dosage concentration of 40 μM.
[0085] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A triterpenoid saponin compound, characterized in that: The triterpenoid saponin compound includes tribenzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside or tribenzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside; The chemical structure of the tri-benzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside is as follows: The chemical structural formula of the tri-benzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside is as follows:
2. A method for extracting triterpenoid saponin compounds as claimed in claim 1, characterized in that: The following steps are involved: The dried raspberry root is crushed and then soaked and extracted with ethanol at room temperature for multiple times, and the soaking liquid is filtered each time, and the soaking liquid is collected and combined, and concentrated under reduced pressure to obtain an extract; The extract is suspended in water to form an aqueous suspension, and extracted with petroleum ether, dichloromethane, ethyl acetate, and n-butanol in sequence, and the extract is separated and concentrated under reduced pressure to obtain an extract of the petroleum ether extraction part, an extract of the dichloromethane extraction part, an extract of the ethyl acetate extraction part, and an extract of the n-butanol extraction part in sequence; The extract of the ethyl acetate extraction part was separated by silica gel column chromatography, and a dichloromethane-methanol mixture was used as an eluent for gradient elution, and thin layer detection was performed, and fractions with similar components were combined to obtain 10 fractions H1 to H10; Fraction H1 was separated by gel column chromatography and eluted with methanol to obtain five secondary fractions H1.1 to H1.5; The triterpenoid saponin compound was prepared by semi-preparative high performance liquid chromatography on fraction H1.
1.
3. The method for extracting triterpenoid saponin compounds according to claim 2, characterized in that: The dried raspberry root is crushed and then soaked and extracted with 92-98% ethanol by volume at room temperature for 2-4 times, and the soaking liquid is filtered each time, and the soaking liquid is collected and combined, and concentrated under reduced pressure to obtain an extract.
4. The method for extracting triterpenoid saponin compounds according to claim 2, characterized in that: The extract is suspended in water to form an aqueous suspension, and extracted with petroleum ether, dichloromethane, ethyl acetate, and n-butanol in sequence. The extract is separated and separated each time to obtain an extract, and concentrated under reduced pressure to obtain an extract of the petroleum ether extraction part, an extract of the dichloromethane extraction part, an extract of the ethyl acetate extraction part, and an extract of the n-butanol extraction part in sequence; wherein each kg of the extract is suspended in 5-10 L of water to form an aqueous suspension, and the volume ratio of the petroleum ether, dichloromethane, ethyl acetate, and n-butanol to water is (1-3):(1-3), respectively.
5. The method for extracting triterpenoid saponin compounds according to claim 2, characterized in that: The extract of the ethyl acetate extraction part is separated by silica gel column chromatography, and in the step of gradient elution using a dichloromethane-methanol mixture as an eluent, the mesh number of the silica gel column is 200-300 meshes, and the volume ratio of dichloromethane to methanol is 30:1-1:
1.
6. The method for extracting triterpenoid saponin compounds according to claim 2, characterized in that: Fraction H1 was separated by Sephadex LH-20 gel column chromatography and eluted with pure methanol to obtain five secondary fractions H1.1 to H1.
5.
7. The method for extracting triterpenoid saponin compounds according to claim 2, characterized in that: The fraction H1.1 was separated by semi-preparative high performance liquid chromatography, using a C18 column with a length of 250 mm, an inner diameter of 10 mm, and a particle diameter of 5 μm for the column filler, and a mixed solution of pure methanol and a 0.01-0.05% by volume formic acid aqueous solution was used as an eluent for isocratic elution to obtain a triterpenoid saponin compound; Collect R The fraction from 31.0 to 33.0 min gave tris-benzyl acid-3β-O-α-L-(2',4'-di-O-acetyl)-arabinopyranoside; Collect R The fraction from 39.0 to 41.0 min gave tri-benzyl acid-3β-O-β-D-(2',3'-di-O-acetyl)-xylopyranoside.
8. The method for extracting triterpenoid saponin compounds according to claim 7, characterized in that: In the step of mixing pure methanol and a formic acid aqueous solution with a volume concentration of 0.01-0.05% to obtain a mixed solution, the volume fraction of methanol in the mixed solution is 68-72%.
9. Use of the triterpenoid saponin compound according to claim 1 in the preparation of health food, functional food or medicine for preventing or treating non-alcoholic fatty liver disease.
